Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines for the treatment of CRC [5] have been recently updated and now include aflibercept as one of the options in the category of VEGF-targeted agents [51]. Here, VEGFA is linked to colorectal carcinoma.